| Wednesday, October 26 | |
|---|---|
| 12:00 – 4:00 | Optional Executive Education Program: Basic Financial Analysis for Life Sciences Professionals Andrew W. Lo, MIT Koch Institute at MIT, 500 Main Street (Building 76), Cambridge, MA 02142 Space is limited to 100 participants on a first-come-first-served basis. | 
| 5:00 – 6:00 | Registration Check-In and Cocktails Boston Marriott Cambridge 2nd Floor Salons, 2 Cambridge Center (50 Broadway), Cambridge, MA 02142 | 
| 6:00 – 8:00 | Welcome Dinner Welcome Remarks: Andrew W. Lo, MIT Opening Remarks: Greg Simon, Cancer Moonshot Task Force Special Presentation: Parag Mallick, Stanfordommons | 
| Thursday, October 27 Samberg Conference Center at MIT, 7th Floor, 50 Memorial Drive (Building E52), Cambridge, MA 02142 | |
|---|---|
| 8:00 – 8:30 | Continental Breakfast and Registration Check-In | 
| 8:30 – 9:00 | Welcome and Conference Background and Objectives Andrew W. Lo, MIT | 
| 9:00 – 10:30 | Session 1 – Where Are We Now and Where Do We Want to Be? Martin Friedman, Pharmakon Advisors; Ansbert Gadicke, MPM Capital; JC Gutierrez-Ramos, Synlogic; Sean Khozin, FDA; Marty Tenenbaum, CancerCommons; Jake Xia, Harvard Management Company | 
| 10:30 – 11:00 | Break | 
| 11:00 – 12:30 | Session 2 – New and Emerging Business Models 1: Public-Private Partnerships Terrance Coyne, Royalty Pharma; Jose Maria Fernandez, Spain’s Treasury Department; Neil Littman, CIRM; Chandra Ramanathan, Bayer; Theodore Schenkelberg, Human Vaccines Project; Jonathan Stamler, Harrington Discovery Institute | 
| 12:30 – 2:00 | Lunch featuring Fireside Chat with Phillip A. Sharp Moderated by Janet Wu | 
| 2:00 – 3:30 | Session 3 – Innovations and Challenges in Translation and Clinical Trial Design Chris Austin, NCATS; Scott Berry, Berry Consultants; Laura Esserman, UCSF; Jonathan Hirsch, Syapse; Monique Mansoura, MIT; Murray Sheldon, FDA | 
| 3:30 – 4:00 | Break | 
| 4:00 – 5:45 | Session 4 – Establishing Criteria: Analytics, Modeling, Structures and Ratings David Agus, USC; Ronald Borod, DLA Piper; Winston Chang, Standard & Poor’s; Mark Gordon, Informa; Nick Marko, Geisinger; Tomas Philipson, University of Chicago; Roger Stein, MIT | 
| 5:45 – 6:00 | Day 1 Conference Wrap-Up | 
| 6:00 | Dinner featuring Fireside Chat with Bob Beall, Cystic Fibrosis Foundation Moderated by Janet Wu Boston Marriott Cambridge 2nd Floor Salons, 2 Cambridge Center (50 Broadway), Cambridge, MA 02142 | 
| Friday, October 28 Samberg Conference Center at MIT, 7th Floor, 50 Memorial Drive (Building E52), Cambridge, MA 02142 | |
|---|---|
| 8:00 – 8:30 | Continental Breakfast | 
| 8:30 – 10:00 | Session 5 – Lessons Learned Christiana Bardon, Burrage Capital; Anna Barker, Arizona State University; Jonathan Benjamin, Amgen; Howard Fingert, Takeda | 
| 10:00 – 10:30 | Break | 
| 10:30 – 12:00 | Session 6 – New and Emerging Business Models 2: Foundations, Patient Advocates, and Other Mission-Driving Organizations Parag Mallick, Stanford; Larry Norton, Memorial Sloan Kettering Cancer Center; Julien de Salaberry, Global Cancer Research and Commercialisation Fund; Lara Sullivan, Pfizer; Laura Thrall, CureSearch | 
| 12:00 – 1:30 | Lunch Keynote Speaker: Chris Viehbacher, Gurnet Point Capital | 
| 1:30 – 3:00 | Session 7 – New and Emerging Business Models 3: Private Sector Innovations Neil Kumar, BridgeBio Capital; Andrew Lee, UBS; Amy Schulman, Polaris Partners; Mayukh Sukhatme, Roivant Sciences; Bill Symonds, Roivant Sciences | 
| 3:00 – 3:30 | Break | 
| 3:30 – 5:00 | Session 8 – Convergence: Innovations in Academia and Commercialization Kevin Grimes, Stanford; Marc Goldberg, BioVentures Investors; Lita Nelsen; Jon Soderstrom, Yale | 
| 5:00 – 5:30 | Day 2 Conference Wrap-Up | 
